New paradigm for prevention of cervical cancer.
Human papillomavirus (HPV) infection is an event responsible for the development of cervical cancer and its premalignant dysplasia. Prophylactic vaccines based on virus-like particles (VLPs) have been successfully tested in clinical trials. They are safe, close to 100% effective in preventing persistent infection and premalignant disease, and are now being introduced onto the market. Vaccination should be offered primarily to young girls and adolescents 9-15 years of age. Vaccine introduction faces particular problems due to a bias towards sexually transmitted diseases and financing, especially in developing countries. However, it represents the first vaccine that has the potential to eradicate 70% of cervical cancer world wide.
Kaufmann
Andreas M
AM
Department of Gynecology, Charité Campus Benjamin Franklin and Campus Mitte, Hindenburgdamm 30, 12200 Berlin, Germany. andreas.kaufmann@charite.de
Schneider
Achim
A
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D015229:Sexually Transmitted Diseases, Viral / Q000276:immunology / Q000517:prevention & control*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines